Crossmark Global Holdings, Inc. Halozyme Therapeutics, Inc. Transaction History

Crossmark Global Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 19, 2023	SELL	$40.06 - $59.44 $168,011 - $249,291	-4,194 Reduced 18.14%	18,928 $1.08 Million
Q3 2022 Nov 01, 2022	SELL	$38.53 - $51.78 $25,198 - $33,864	-654 Reduced 2.75%	23,122 $914,000
Q2 2022 Jul 29, 2022	SELL	$37.35 - $48.3 $102,712 - $132,825	-2,750 Reduced 10.37%	23,776 $1.05 Million
Q1 2022 May 11, 2022	BUY	$31.97 - $41.06 $142,266 - $182,717	4,450 Added 20.16%	26,526 $1.06 Million
Q4 2021 Jan 10, 2022	BUY	$31.82 - $40.75 $56,003 - $71,720	1,760 Added 8.66%	22,076 $888,000
Q3 2021 Oct 21, 2021	BUY	$38.47 - $46.42 $781,556 - $943,068	20,316 New	20,316 $826,000
Q3 2021 Oct 13, 2021	SELL	$38.47 - $46.42 $779,786 - $940,933	-20,270 Closed	0 $0
Q2 2021 Jul 21, 2021	SELL	$38.84 - $51.31 $1,165 - $1,539	-30 Reduced 0.15%	20,270 $920,000
Q1 2021 Apr 15, 2021	BUY	$39.51 - $51.45 $13,038 - $16,978	330 Added 1.65%	20,300 $846,000
Q4 2020 Jan 14, 2021	BUY	$25.81 - $43.62 $515,425 - $871,091	19,970 New	19,970 $853,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.